Orexigen Therapeutics, Inc. to Present at the JMP Securities Healthcare Conference
SAN DIEGO, July 3, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, July 10th at 9 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Orexigen Contact: | Media Contact: |
McDavid Stilwell | Denise Powell |
VP, Corporate Communications and Business Development | BrewLife |
(858) 875-8629 | (510) 703-9491 |
SOURCE Orexigen Therapeutics, Inc.
Help employers find you! Check out all the jobs and post your resume.